About the Company
akero therapeutics is developing best-in-class medicines that restore metabolic balance to treat non-alcoholic steatohepatitis (nash) and other serious metabolic diseases. akero's lead clinical program, akr-001, is a long-acting fc fusion modified fgf21 protein and potential best-in-class treatment for nash. akr-001 builds upon two decades of work on fgf21 biology. it is designed to affect both the liver and adipose tissue, reducing liver fat and suppressing inflammation and fibrosis.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $AKRO News
Akero Therapeutics' Stock Is Soaring Monday - Here's Why
Akero Therapeutics Inc (NASDAQ:AKRO) shares are trading higher after the company released preliminary topline week 96 results ...
Akero (AKRO) Up on Upbeat Week 96 Data From Liver Disease Study
Akero Therapeutics, Inc. AKRO announced a statistically significant histological improvement in the primary endpoint of its ...
Akero Therapeutics, Inc.
Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm's lead product candidate, efruxifermin (EFX) ...
2 Bay Area biotechs look to raise collective $550 million following deal, trial news
These Bay Area biotechs are hoping to raise $550 million between them on the back of some positive news developments. Here's ...
Akero Therapeutics Commences Public Offering Of $300 Mln Of Shares
Akero Therapeutics Inc. (AKRO) said that it has commenced an underwritten public offering of $300.0 million of shares of its common ...
Akero Therapeutics Announces Pricing of Public Offering of Common Stock
J.P. Morgan, Morgan Stanley, Jefferies and Evercore ISI are acting as joint book-running managers for the offering.
Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
EFX groups demonstrated ≥1 stage improvement in fibrosis without worsening of MASH, approximately three- and two-fold the ...
Akero Therapeutics Stock (NASDAQ:AKRO), Quotes and News Summary
Akero Therapeutics success in HARMONY Phase 2b study ... Shares of Super Micro Computer, Inc. (NASDAQ: SMCI) rose sharply in today’s pre-market trading. Avi Kapoor Why MercadoLibre Shares ...
Akero Therapeutics Inc.: Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology
March 07, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease, today announced ...
Akero Therapeutics Inc AKRO
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Akero Therapeutics Announces Pricing of Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious ...
Akero Therapeutics Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious ...
Loading the latest forecasts...